Intervention Protocol

Ofatumumab for rheumatoid arthritis

  1. Vidhu Anand1,*,
  2. Sushil K Garg1,
  3. Maria Angeles Lopez-Olivo2,
  4. Jasvinder A Singh3

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 17 NOV 2013

DOI: 10.1002/14651858.CD010833

How to Cite

Anand V, Garg SK, Lopez-Olivo MA, Singh JA. Ofatumumab for rheumatoid arthritis (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD010833. DOI: 10.1002/14651858.CD010833.

Author Information

  1. 1

    University of Minnesota, Department of Surgery, Minneapolis, MN, USA

  2. 2

    The University of Texas, M.D. Anderson Cancer Center, Department of General Internal Medicine, Houston, Texas, USA

  3. 3

    Birmingham VA Medical Center, Department of Medicine, Birmingham, USA

*Vidhu Anand, Department of Surgery, University of Minnesota, 515 Delaware Street, 11-196 Moos Tower, Minneapolis, MN, 55455, USA.

Publication History

  1. Publication Status: New
  2. Published Online: 17 NOV 2013




  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the benefits and harms of ofatumumab in reducing disease activity, pain, and improving function in people with RA.